Sandoz Group (OTCMKTS:SDZNY) Rating Increased to Strong-Buy at Erste Group Bank

Sandoz Group (OTCMKTS:SDZNY) was upgraded by investment analysts at Erste Group Bank to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

Separately, Barclays upgraded Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Four analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Sandoz Group Trading Down 3.0%

Shares of OTCMKTS SDZNY opened at $85.14 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.18 and a quick ratio of 0.77. The firm’s 50-day moving average price is $85.86 and its two-hundred day moving average price is $83.75. Sandoz Group has a 52-week low of $55.42 and a 52-week high of $94.15.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.